Jiangsu Jibeier Pharmaceutical Co., Ltd. (SHA:688566)
27.96
-0.08 (-0.29%)
Apr 29, 2026, 3:00 PM CST
SHA:688566 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 689.16 | 781.32 | 847.48 | 694.87 | 903.9 | 1,025 |
Trading Asset Securities | 81.09 | 37.03 | 56 | 35 | 90 | 200 |
Cash & Short-Term Investments | 770.25 | 818.36 | 903.48 | 729.87 | 993.9 | 1,225 |
Cash Growth | -16.87% | -9.42% | 23.79% | -26.57% | -18.87% | -4.84% |
Accounts Receivable | 401.84 | 366.28 | 300.75 | 369.15 | 216.21 | 146.6 |
Other Receivables | 0.44 | 1.39 | 0.05 | 0.03 | 0.02 | - |
Receivables | 402.28 | 367.66 | 300.8 | 369.17 | 216.23 | 146.6 |
Inventory | 36.78 | 34.07 | 30.7 | 29.51 | 32.66 | 31.83 |
Other Current Assets | 47.07 | 34.47 | 69.46 | 2.59 | 13.98 | 2.62 |
Total Current Assets | 1,256 | 1,255 | 1,304 | 1,131 | 1,257 | 1,406 |
Property, Plant & Equipment | 1,040 | 1,031 | 986.86 | 832.49 | 552.21 | 271.51 |
Long-Term Investments | 84.47 | 85.94 | 79.79 | 126.19 | 61.74 | 56.63 |
Goodwill | 35.33 | 35.33 | - | - | - | - |
Other Intangible Assets | 57.59 | 58.03 | 56.69 | 58.2 | 59.74 | 61.28 |
Long-Term Deferred Tax Assets | 24.35 | 22.64 | 17.93 | 16.13 | 15.59 | 11.72 |
Long-Term Deferred Charges | 63.28 | 59.74 | 32.14 | 1.13 | 2.18 | 3.25 |
Other Long-Term Assets | 161.71 | 170.19 | 49.69 | 44.38 | 16.34 | 8.21 |
Total Assets | 2,723 | 2,717 | 2,528 | 2,210 | 1,965 | 1,819 |
Accounts Payable | 64.35 | 74.29 | 97.15 | 91.22 | 101.67 | 69.92 |
Accrued Expenses | 11.36 | 25.27 | 45.73 | 86.79 | 53.49 | 35.3 |
Short-Term Debt | 1.68 | 16.52 | 20.83 | 9.91 | - | - |
Current Income Taxes Payable | 27.77 | 34.07 | 2.01 | 0.19 | 6.09 | 5.19 |
Current Unearned Revenue | 5.05 | 6.4 | 0.95 | 1.81 | 3.42 | 1.51 |
Other Current Liabilities | 24.09 | 20.47 | 18.53 | 20.39 | 16.69 | 12.14 |
Total Current Liabilities | 134.31 | 177.01 | 185.19 | 210.31 | 181.36 | 124.06 |
Long-Term Debt | - | 2.2 | - | - | - | - |
Long-Term Unearned Revenue | 58.71 | 58.39 | 58.59 | 59.04 | 58.85 | 59.7 |
Long-Term Deferred Tax Liabilities | 3.09 | 3.23 | 3.25 | 3.25 | 3.4 | - |
Other Long-Term Liabilities | 26.64 | 26.64 | 26.64 | 26.64 | 26.64 | 26.64 |
Total Liabilities | 222.75 | 267.47 | 273.68 | 299.25 | 270.24 | 210.4 |
Common Stock | 199.43 | 199.43 | 199.43 | 189.08 | 186.94 | 186.94 |
Additional Paid-In Capital | 1,332 | 1,323 | 1,299 | 1,082 | 1,042 | 1,021 |
Retained Earnings | 949.67 | 907.68 | 749.77 | 633.4 | 459.17 | 394.24 |
Comprehensive Income & Other | 0.07 | 0.01 | - | - | - | - |
Total Common Equity | 2,481 | 2,430 | 2,249 | 1,905 | 1,688 | 1,602 |
Minority Interest | 18.6 | 19.6 | 5.23 | 5.58 | 5.9 | 6.31 |
Shareholders' Equity | 2,500 | 2,450 | 2,254 | 1,910 | 1,694 | 1,608 |
Total Liabilities & Equity | 2,723 | 2,717 | 2,528 | 2,210 | 1,965 | 1,819 |
Total Debt | 1.68 | 18.72 | 20.83 | 9.91 | - | - |
Net Cash (Debt) | 768.56 | 799.64 | 882.65 | 719.96 | 993.9 | 1,225 |
Net Cash Growth | -14.87% | -9.40% | 22.60% | -27.56% | -18.87% | -4.84% |
Net Cash Per Share | 3.84 | 4.00 | 4.55 | 3.84 | 5.33 | 6.50 |
Filing Date Shares Outstanding | 199.97 | 199.43 | 199.43 | 189.08 | 186.94 | 186.94 |
Total Common Shares Outstanding | 199.97 | 199.43 | 199.43 | 189.08 | 186.94 | 186.94 |
Working Capital | 1,122 | 1,078 | 1,119 | 920.84 | 1,075 | 1,282 |
Book Value Per Share | 12.41 | 12.18 | 11.28 | 10.07 | 9.03 | 8.57 |
Tangible Book Value | 2,389 | 2,337 | 2,192 | 1,847 | 1,629 | 1,541 |
Tangible Book Value Per Share | 11.94 | 11.72 | 10.99 | 9.77 | 8.71 | 8.24 |
Buildings | - | - | 142.66 | 142.66 | 142.52 | 142.52 |
Machinery | - | - | 75.26 | 74.81 | 73.37 | 72.78 |
Construction In Progress | - | - | 917.62 | 754.62 | 466.36 | 175.48 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.